-
公开(公告)号：KR1020090085350A
公开(公告)日：2009-08-07
申请号：KR1020080011190
申请日：2008-02-04
Applicant: 서울대학교산학협력단
IPC: C12Q1/68
CPC classification number: C12Q1/686 , C12Q1/6827
Abstract: A method for screening a nontuberculous mycobacteria is provided to directly detect the nontuberculous mycobacteria from sputum by the Nested PCR-Direct Sequencing(NPDS). A method for screening a nontuberculous mycobacteria comprises: a step of producing PCR product which is specific to the nontuberculous mycobacteria in heat shock protein 65 (HSP65) gene comprising total 1623 bp of mycobacterium sp. a step of amplifying gene fragment with a primer which specifically amplifies the gene fragment; a step of analyzing gene sequence; and a step of comparing 423th sequence, 424 sequence, or 701 sequence.
Abstract translation: 提供筛选非结核分枝杆菌的方法，通过嵌套PCR直接测序（NPDS）直接检测来自痰液的非结核分枝杆菌。 筛选非结核分枝杆菌的方法包括：在热休克蛋白65（HSP65）基因中产生特异于非结核分枝杆菌的PCR产物的步骤，其包含总共1623bp的分枝杆菌属。 用特异性扩增基因片段的引物扩增基因片段的步骤; 分析基因序列的步骤; 以及比较423号序列，424序列或701序列的步骤。
-
公开(公告)号：KR1020210010090A
公开(公告)日：2021-01-27
申请号：KR1020190087522
申请日：2019-07-19
Applicant: 대한민국(질병관리청장) , 서울대학교산학협력단
Abstract: 본발명은마이코박테리움안얀젠스(Mycobacterium anyangense) 균주를포함하는결핵치료용백신조성물에관한것으로, 본발명의일 측면에서제공되는마이코박테리움안얀젠스(Mycobacterium anyangense) 균주기반결핵치료용백신조성물은현재결핵백신으로사용되고있는 M. bovis BCG에비해안전성이우수하며, 치료제단독처리그룹에비해결핵치료효과가우수하므로, 치료백신후보물질로더욱우수한치료효과를확보할수 있는효과가있다.
-
-
公开(公告)号：KR1020170092216A
公开(公告)日：2017-08-11
申请号：KR1020160013264
申请日：2016-02-03
Applicant: 서울대학교산학협력단
IPC: C12Q1/68
Abstract: 본발명은 PCR을이용한균종을분리동정방법에관한것에관한것으로, 본발명의방법에의하여임상적으로균종의균주들을아종또는유전자형수준으로분류할수 있어, 항생제치료효과를높일수 있다.
Abstract translation: 本发明涉及的物种通过PCR的识别方法的分离，就可以通过本发明的具有亚种或基因型水平的方法中的物种的临床菌株进行分类，可增强抗生素疗法的有效性。
-
公开(公告)号：KR1020160021933A
公开(公告)日：2016-02-29
申请号：KR1020140106951
申请日：2014-08-18
Applicant: 서울대학교산학협력단
Abstract: 본원은온도민감성미코박테리아인(strain 49061) 균주및 이를포함하는백신조성물을개시한다. 본원에따른백신은접종시피부및 피하에서는증식을하여면역을자극시키지만체내중심부에서는체온보다낮은온도에서만자랄수 있는특징으로인해증식이억제되어감염의가능성이낮아, 마이코박테리아로인한질환의예방백신및 면역치료에안전하고유용하게사용될수 있다.
Abstract translation: 在本发明中公开了一种作为温度敏感性分枝杆菌的M.paragordonae（菌株49061）菌株和包含该菌株的疫苗组合物。 根据本发明的疫苗通过在接种时在皮肤或皮肤下传播而刺激免疫，但是由于仅在低于体温的温度下生长的特征而在身体的中心传播，并且具有 感染的可能性低，从而安全有效地用作预防分枝杆菌引起的疾病的疫苗，并用于免疫治疗。
-
Patent Agency Ranking
公开(公告)号：KR1020130113046A
公开(公告)日：2013-10-15
申请号：KR1020120035318
申请日：2012-04-05
Applicant: 서울대학교산학협력단
CPC classification number: C12Q1/706 , C12Q1/6886 , C12Q2600/118
Abstract: PURPOSE: A marker for diagnosing liver diseases and a method for detecting the same are provided to early and effectively predict susceptibility with respect to liver cancer in a patient with HBV infection or to diagnose liver cancer. CONSTITUTION: A marker for diagnosing liver diseases contains a polynucleotide which is selected among: a polynucleotide with 10-200 continuous bases containing base sequences encoding one or more coding corresponding to 5^th, 83^th, 97^th, 100^th, 182^th, and 184^th mutant amino acids of core protein C region of HBV and 28^th mutant amino acid of preC region; and a complementary polynucleotide thereof. Each amino acid residue number is determined by a residue order corresponding to preC and C regions among genotypes A to H. A kit for diagnosing liver diseases contains the polynucleotide.
Abstract translation: 目的：提供用于诊断肝脏疾病的标记及其检测方法，以早期有效预测HBV感染患者肝癌的易感性或诊断肝癌。 构成：用于诊断肝脏疾病的标志物含有选自以下的多核苷酸：具有10-200个连续碱基的多核苷酸，其含有编码一个或多个编码对应于5 ^，83 ^，97 ^，100 ^ 第182位和第184位突变型氨基酸的HBV核心蛋白C区和第28突变氨基酸的前C区; 及其互补多核苷酸。 每个氨基酸残基数是通过对应于基因型A至H中的前C和C区的残基顺序确定的。用于诊断肝脏疾病的试剂盒含有多核苷酸。
-
公开(公告)号：KR101248426B1
公开(公告)日：2013-03-28
申请号：KR1020100085942
申请日：2010-09-02
Applicant: 서울대학교산학협력단
IPC: C12Q1/68 , C12N15/11 , G01N33/576
Abstract: 본 발명은 HBe 항원 음성 만성 B형 간염 환자에 특이적인 HBV로부터 유래된 변이된 S 항원 유전자 또는 단백질을 검출하여, HBe 항원 음성 만성 B형 간염 및 이로부터 유래된 간질환을 진단할 수 있는 진단용 키트에 관한 것이다. 본 발명의 HBe 항원 음성 만성 B형 간염 진단용 키트를 사용할 경우, HBe 항원 음성 만성 B형 간염에 특이적인 변이된 HBV S 항원 유전자 또는 단백질을 용이하게 검출할 수 있으므로, 변이된 S 항원 유전자 또는 단백질을 포함하는 HBV에 의하여 발병되는 HBe 항원 음성 만성 B형 간염 및 이로부터 유래된 간질환을 조기에 효과적으로 진단할 수 있을 것이다.
-
公开(公告)号：KR1020120119307A
公开(公告)日：2012-10-31
申请号：KR1020110037147
申请日：2011-04-21
Applicant: 서울대학교산학협력단
CPC classification number: C12N15/74
Abstract: PURPOSE: A mycobacteria-E.coli shuttle vector is provided to effectively deliver DNA or recombinant proteins and to be used as an immunotherapeutic agent. CONSTITUTION: A mycobacteria-derived replicable DNA nucleic acid molecule has a nucleotide sequence of sequence number 1. The shuttle vector contains: an origin of replication containing a nucleotide sequence(oriM) of sequence number 2; a replication origin for prokaryote; a promoter, and an operatively linked expression subject-coding nucleotide. The nucleotide sequence(oriM) contains AT-rich region and direct repeat region. The expression subject-coding nucleotide is a reporter protein, antisense oligonucleotide, siRNA, shRNA, miRNA, or piRNA. The shuttle vector additionally contains a selection marker.
Abstract translation: 目的：提供分枝杆菌 - 大肠杆菌穿梭载体以有效递送DNA或重组蛋白，并用作免疫治疗剂。 构成：分枝杆菌衍生的可复制DNA核酸分子具有序列号1的核苷酸序列。穿梭载体包含：含有序列号2的核苷酸序列（oriM）的复制起点; 原核生物的复制起点; 启动子和可操作连接的表达受试者编码核苷酸。 核苷酸序列（oriM）含有富含AT的区域和直接重复区域。 表达主体编码核苷酸是报告蛋白，反义寡核苷酸，siRNA，shRNA，miRNA或piRNA。 穿梭载体另外包含选择标记。
-
公开(公告)号：KR1020120065769A
公开(公告)日：2012-06-21
申请号：KR1020100127062
申请日：2010-12-13
Applicant: 서울대학교산학협력단
IPC: C12N5/10 , C12N5/09 , C12N15/51 , A01K67/027
Abstract: PURPOSE: A cancer cell line which expresses male-specific W4P preS1 is provided to continuously express coat antigen proteins. CONSTITUTION: A W4P preS1 transformed cell line is prepared by transforming with a nucleotide sequence encoding W4P preS1 mutant protein and causes solid cancer in an animal. The transformed cell line is a mouse, rat, goat, sheep, cow, horse, pig, or human-derived animal cell line. The cell line is syngeneic cells to a cancer animal model. A method for preparing the transformed cell line comprises: a step of transforming animal cells with a recombinant vector containing the nucleotide and a promoter which is operatively linked to the nucleotide.
Abstract translation: 目的：提供表达男性特异性W4P前S1的癌细胞系，以连续表达外壳抗原蛋白。 构成：通过用编码W4P preS1突变蛋白的核苷酸序列转化并在动物中引起固体癌来制备W4P preS1转化的细胞系。 转化细胞系是小鼠，大鼠，山羊，绵羊，牛，马，猪或人源动物细胞系。 细胞系是与癌症动物模型的同基因细胞。 用于制备转化细胞系的方法包括：用含有核苷酸的重组载体和与核苷酸有效连接的启动子转化动物细胞的步骤。
-
公开(公告)号：KR1020110027977A
公开(公告)日：2011-03-17
申请号：KR1020090085849
申请日：2009-09-11
Applicant: 현대자동차주식회사 , 기아자동차주식회사 , 서울대학교산학협력단
IPC: H01M8/04
Abstract: PURPOSE: A humidification system for a fuel cell is provided to achieve film humidification of exhaust air exhausted from a fuel cell stack and recycling humidification through the recycling of exhaust air and to control a humidification amount according to the driving condition of a fuel cell system. CONSTITUTION: A humidification system(100) for a fuel cell supplies high temperature moisture-containing exhaust air exhausted from a fuel cell stack(10) to a membrane humidifier(70). In the membrane humidifier, the humidification of exhaust air is performed. The humidified air is supplied to a fuel cell stack. The exhaust air with low humidity is exhausted. Some of the exhaust air is recycled and the humidification of the feed air is performed by the exhaust air. The humidified air is supplied to the membrane humidifier.
Abstract translation: 目的：提供一种用于燃料电池的加湿系统，以实现从燃料电池堆排出的废气的薄膜加湿，并通过再循环排气再循环加湿，并根据燃料电池系统的驱动条件来控制加湿量。 构成：用于燃料电池的加湿系统（100）将从燃料电池堆（10）排出的高温含水废气排放到膜加湿器（70）。 在膜加湿器中，进行排气的加湿。 加湿的空气被供应到燃料电池堆。 低湿度的排气被耗尽。 一些废气被再循环，并且进气的加湿由废气进行。 将加湿空气供给到膜加湿器。
-
-
-
-
-
-
-
-
-
Search Results
60
records
(took 0.034 seconds)
